药学学报, 2020, 55(3): 349-354
引用本文:
王赫然, 王茜. 新型冠状病毒有关药物和生物制品研究进展[J]. 药学学报, 2020, 55(3): 349-354.
WANG He-ran, WANG Xi. Advances in research of novel coronavirus related drugs and biological products[J]. Acta Pharmaceutica Sinica, 2020, 55(3): 349-354.

新型冠状病毒有关药物和生物制品研究进展
王赫然, 王茜
科学技术部火炬高技术产业开发中心, 北京 100045
摘要:
自2019年12月发现新型冠状病毒肺炎患者起,至2020年2月21日新冠病毒肺炎疫情已扩散至27个国家,全球患者总数近8万人。此次疫情受到世界各国广泛关注,为了有效应对疫情,各国正组织科研攻关,特别是在治疗药物筛选和疫苗研发等方面加大攻关力度,这是控制疫情的重点和难点。本文收集整理了各国学术界和政府关于药物和生物制品的相关研究信息,主要围绕可能用于治疗新型冠状病毒肺炎的化学药、中药和生物制品的研究情况,供有关部门、单位和科技人员参考。
关键词:    新型冠状病毒      抗病毒药物      中药      疫苗     
Advances in research of novel coronavirus related drugs and biological products
WANG He-ran, WANG Xi
Torch High Technology Industry Development Center, Ministry of Science and Technology, Beijing 100045, China
Abstract:
The novel coronavirus pneumonia was first discovered in December 2019. By February 21, 2020, the virus had spread to 27 countries, and the total number of patients were nearly 80 thousands. In order to effec-tively prevent and control the epidemic, countries around the world are organizing scientific research, especially in screening of therapeutic drugs, researching and developing of vaccine, which is the key point and difficulty of epidemic control. On the basis of a large number of relevantly collected information about drugs and biological products in the academia and the press of various countries, this paper focus on the research status and develop-ment of antiviral chemical drugs, Chinese traditional medicines and biological products, aiming to provide refer-ence for relevant departments, units and scientists.
Key words:    novel coronavirus    antiviral drug    Chinese traditional medicine    vaccine   
收稿日期: 2020-02-18
DOI: 10.16438/j.0513-4870.2020-0137
通讯作者: 王赫然,Tel:86-10-88656258,E-mail:wanghr@ctp.gov.cn
Email: wanghr@ctp.gov.cn
相关功能
PDF(370KB) Free
打印本文
0
作者相关文章
王赫然  在本刊中的所有文章
王茜  在本刊中的所有文章

参考文献:
[1] Huang CL, Wang YM, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395:497-506.
[2] Sayers EW, Beck J, Brister JR, et al. Database resources of the National Center for Biotechnology Information[J]. Nucl Acids Res, 2020, 48:D9-D16.
[3] National Health Commission of the People's Republic of China. Pneumonia epidemic situation of new coronavirus infection on February 21, 2020[EB/OL]. 2020-02-21. http://www.nhc.gov.cn/xcs/yqfkdt/202002/543cc508978a48d2b9322bdc83daa6fd.shtml.
[4] Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerg Microbes Infect, 2020, 9:221-236.
[5] Liu B, Qin ZL, Qi ZT. Genomic structure and proteinic functions of 2019 novel coronavirus[J]. Microbes Infect, 2020, 15:81-91.
[6] Xu XT, Chen P, Wang JF, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J]. Sci China Life Sci (中国科学:生命科学), 2020. DOI:10.1007/s11427-020-1637-5.
[7] Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread[J]. Virol J, 2005, 2:69.
[8] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Res, 2020. DOI:10.1038/s41422-020-0282-0.
[9] Liu S, Xiao G, Chen Y, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus:implications for virus fusogenic mechanism and identification of fusion inhibitors[J]. Lancet, 2004, 363:938-947.
[10] Zumla A, Chan JF, Azhar EI, et al. Coronaviruses-drug discovery and therapeutic options[J]. Nat Rev Drug Discov, 2016, 15:327-347.
[11] Park JY, Ko JA, Kim DW, et al. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV[J]. J Enzyme Inhib Med Chem, 2016, 31:23-30.
[12] Riccio F, Talapatra SK, Oxenford S, et al. Development and validation of RdRp Screen, a crystallization screen for viral RNA-dependent RNA polymerases[J]. Biol Open, 2019. DOI:10.1242/bio.037663.
[13] Michelle LH, Chas DB, Scott L, et al. First case of 2019 novel coronavirus in the United States[J]. N Engl J Med, 2020. DOI:10.1056/NEJMoa2001191.
[14] De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections[J]. Chem Asian J, 2019, 14:3962-3968.
[15] Smith EC, Blanc H, Surdel MC, et al. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis:evidence for proofreading and potential therapeutics[J]. PLoS Pathog, 2013, 9:e1003565.
[16] Amy M. More than 80 clinical trials launch to test coronavirus treatments[J]. Nature, 2020, 578:347-348.
[17] Wang ZW, Chen XR, Lu YF, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment[J]. Biosci Trends, 2020. DOI:10.5582/bst.2020.01030.
[18] National Health Commission of the People's Republic of China. Notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 6[EB/OL]. 2020-02-21. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
[19] Yao KT, Liu MY, Li X, et al. Retrospective clinical analysis on treatment of novel coronavirus-infected pneumonia with traditional Chinese medicine Lianhua Qingwen[J]. Chin J Exp Tradi Med Form (中国实验方剂学杂志), 2020. DOI:10.13422/j.cnki.syfjx.20201099.
[20] Xia WG, An CQ, Zheng CJ, et al. Clinical study on 34 novel coronavirus pneumoniae treated with integrated traditional Chinese and Western medicine[J]. J Tradit Chin Med (中医杂志), 2020. http://kns.cnki.net/kcms/detail/11.2166.R.20200217.1502.004.html.
[21] Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds[J]. J Clin Virol, 2004, 31:69-75.
[22] Cinatl J, Morgenstern B, Bauer G, et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus[J]. Lancet, 2003, 361:2045-2046.
[23] Ma X, Bi S, Wang Y, et al. Combined adjuvant effect of ginseng stem-leaf saponins and selenium on immune responses to a live bivalent vaccine of Newcastle disease virus and infectious bronchitis virus in chickens[J]. Poult Sci, 2019, 98:3548-3556.
[24] Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong[J]. Eur J Clin Microbiol Infect Dis, 2005, 24:44-46.
[25] Zumla A, Azhar EI, Arabi Y, et al. Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections[J]. Int J Infect Dis, 2015, 40:71-74.
[26] Bao M, Zhang Y, Wan M, et al. Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide[J]. Clin Immunol, 2006, 118:180-187.
[27] Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J]. Nat Commun, 2020, 11:222.
[28] Li Y, Wan Y, Liu P, et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein[J]. Cell Res, 2015, 25:1237-1249.
[29] Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody[J]. Emerg Microbes Infect, 2020, 9:382-385.
[30] de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS:recent insights into emerging coronaviruses[J]. Nat Rev Microbiol, 2016, 14:523-534.
[31] Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine gargets for 2019-nCoV based on SARS-CoV immunological studies[J]. bioRxiv, 2020. DOI:10.1101/2020. 02.03.933226.
[32] Ramaiah A, Arumugaswami V. Insights into cross-species evolution of novel human coronavirus 2019-nCoV and defining immune determinants for vaccine development[J]. bioRxiv, 2020. DOI:10.1101/2020.01.29.925867.
[33] Pogrebnyak N, Golovkin M, Andrianov V, et al. Severe acute respiratory syndrome (SARS) S protein production in plants:development of recombinant vaccine[J]. Proc Nat Acad Sci, 2005, 102:9062-9067.
[34] Yang Z, Kong W, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice[J]. Nature, 2004, 428:561-564.
[35] Faber M, Lamirande EW, Roberts A, et al. A single immuniza-tion with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing anti-bodies[J]. J Gen Virol, 2005, 86:1435-1440.
[36] Clarivate. Novel coronavirus research resource column[EB/OL]. 2020-02-17. http://clarivate.com.cn/coronavirus-resources/index.htm.
[37] Zhao WM, Song SH, Chen ML, et al. The 2019 novel coronavirus resource[J]. Hereditas (遗传), 2020. DOI:10.16288/j.yczz. 20-030.
相关文献:
1.杨璐, 王辉强, 李玉环.COVID-19治疗药物的研究进展[J]. 药学学报, 2020,55(6): 1081-1090
2.宗阳, 姚卫峰, 居文政.基于细胞因子风暴和中医“湿毒犯肺”理论挖掘抗新型冠状病毒肺炎中药[J]. 药学学报, 2020,55(6): 1091-1097